DDInter1400 DDInter1658
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Pazopanib {u} (Compound) treats {v} (Disease) kidney cancer
Pazopanib {u} (Compound) binds {v} (Gene) PIP4K2C
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C8 Inhibitors
Pazopanib {u} (Compound) downregulates {v} (Gene) MEST
Pazopanib {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Pazopanib (Compound) treats kidney cancer (Disease)
Pazopanib (Compound) binds PIP4K2C (Gene)
Pazopanib (Compound) upregulates SRC (Gene)
Pazopanib (Compound) is included by Cytochrome P450 2C8 Inhibitors (Pharmacologic Class)
Pazopanib (Compound) downregulates MEST (Gene)
Pazopanib (Compound) causes Rhinorrhoea (Side Effect)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab